Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” ...

Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Twist Bioscience in a research ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Doximity ...

Rep. Ro Khanna (D-Calif.) joins 'Squawk Box' to discuss President Trump's third week back in office, DOGE and Elon Musk's efforts to downsize the federal government, working across the aisle in the ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

With a volume of 12,212,671, the price of MRK is down -1.44% at $88.38. RSI indicators hint that the underlying stock may be ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of AbbVie in a research note issued to investors on Monday, February 3rd. Leerink ...